LifeSci Capital Maintains Verve Therapeutics(VERV.US) With Buy Rating, Maintains Target Price $21

Moomoo NewsFeb 28 12:33 ET · Ratings

Promising Progress and Strategic Partnerships Position Verve Therapeutics as a Compelling Buy Opportunity

TipRanksFeb 28 12:05 ET

BMO Capital Maintains Verve Therapeutics(VERV.US) With Buy Rating, Maintains Target Price $30

Moomoo NewsFeb 28 08:31 ET · Ratings

Verve Therapeutics Analyst Ratings

BenzingaFeb 28 07:29 ET · Ratings

H.C. Wainwright Maintains Verve Therapeutics(VERV.US) With Buy Rating, Raises Target Price to $15

Moomoo NewsFeb 28 06:34 ET · Ratings

Express News | Verve Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $15 From $14

ReutersFeb 28 06:19 ET